This HTML5 document contains 42 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB02256/identifier/chebi/
n11http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n14http://linked.opendata.cz/resource/drugbank/drug/DB02256/identifier/pdb/
n7http://linked.opendata.cz/resource/drugbank/drug/DB02256/identifier/kegg-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n15http://linked.opendata.cz/resource/drugbank/drug/DB02256/identifier/pubchem-compound/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n8http://linked.opendata.cz/resource/drugbank/drug/DB02256/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://linked.opendata.cz/resource/drugbank/drug/DB02256/identifier/drugbank/

Statements

Subject Item
n2:DB02256
rdf:type
n3:Drug
n3:description
2'-Deoxyuridine. An antimetabolite that is converted to deoxyuridine triphosphate during DNA synthesis. Laboratory suppression of deoxyuridine is used to diagnose megaloblastic anemias due to vitamin B12 and folate deficiencies. [PubChem]
n3:group
experimental
owl:sameAs
n11:DB02256 n12:DB02256
dcterms:title
2'-Deoxyuridine
adms:identifier
n6:DB02256 n7:C00526 n8:46506680 n9:16450 n14:DUR n15:1263358
n3:synthesisReference
Kenzo Watanabe, Yoshinori Kato, Masahiko Saito, Takeo Oba, Hisashi Fukushima, Takeshi Hara, "5-fluoro-2'-deoxyuridine derivatives and a process for the preparation thereof." U.S. Patent US4605645, issued May, 1984.
n3:IUPAC-Name
n4:271B4C4B-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4C51-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4C50-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4C4D-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4C4E-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4C4F-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4C49-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4C4A-363D-11E5-9242-09173F13E4C5 n4:271B4C47-363D-11E5-9242-09173F13E4C5 n4:271B4C62-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4C48-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4C57-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4C58-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4C52-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4C53-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4C55-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4C54-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4C56-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
951-78-0
n3:Bioavailability
n4:271B4C5D-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4C5F-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4C60-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4C61-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4C5C-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4C5B-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4C5E-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4C4C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4C59-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4C5A-363D-11E5-9242-09173F13E4C5